MedTrace Logo

Evaluation of 68Ga-PSMA PET-CT in the Initial Staging of Advanced Renal Cell Carcinomas - A Prospective, Multicentre, Open-label Study

NCT07624578 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2026-06-03

No results posted yet for this study

Summary

Kidney cancer in adults is the seventh leading cause of cancer-related death in France. Early and accurate imaging of the primary tumour and the identification of metastatic sites are major prognostic factors that are crucial for determining the appropriate stage-specific treatment. However, the diagnosis of sub-centimetre metastatic lymph nodes and occult metastatic lesions remains difficult with current imaging methods. Recent publications have shown promising results for 68Ga-PSMA PET-CT in the detection of metastases from renal cell carcinoma (RCC). It is therefore necessary to develop a new, more sensitive and specific imaging method to detect occult metastatic foci, enabling the earlier initiation of specific systemic or local treatment, and thereby improving survival in these patients or even achieving prolonged remission in oligometastatic cases Experience and acceptability of a new organisational model in primary care: participatory multi-professional health centres

Conditions

  • Kidney Cancers

Interventions

DIAGNOSTIC_TEST

68Ga-PSMA PET-CT scan

A 68Ga-PSMA PET-CT scan will be performed on all patients newly diagnosed with advanced, clinically non-metastatic CRC who have passed the baseline examinations

Sponsors & Collaborators

  • Assistance Publique Hopitaux De Marseille

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2022-02-28
Completion
2022-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07624578 on ClinicalTrials.gov